Poised Realm Patent

google | CROSS-REFERENCE TO RELATED APPLICATIONS

• [0001]
  This application claims the benefit of U.S. Provisional Application Nos. 61/367,781, filed Jul. 26, 2010; 61/367,779, filed Jul. 26, 2010; 61/416,723, filed Nov. 23, 2010; 61/420,720, filed Dec. 7, 2010; and 61/431,420, filed Jan. 10, 2011, all of which are incorporated herein by reference in their entirety.
BACKGROUND
• [0002]
  1. Field of the Invention
• [0003]
  The present invention relates to systems and uses of systems operating between fully quantum coherent and fully classical states. Non-limiting applications include drug discovery, computers, and artificial intelligence.
• [0004]
  2. Background Description
• [0005]
  Many physical systems having quantum degrees of freedom quickly decohere to classicity for all practical purposes. Thus, many designed systems consider only classical behaviors. One example is in the field of drug discovery where traditional approaches to drug design considers the lock-and-key fitting of a molecule into an enzyme or receptor. Other designed systems are carefully setup to maintain full quantum coherence, for example, the qubits in a quantum computer. However, recent discoveries have indicated several systems in nature that have relatively slow decoherence. Birds are able to see magnetic field lines due to a quantum coherent chemical reaction in their retina. Light harvesting molecules are able to maintain quantum coherent electron transport for times much longer than the expected coherence time at room temperatures. The existence of such cases demonstrates that quantum coherence can exist at room temperature and at the presence of water bath and evolution can ‘design’ quantum coherent structures to play certain biological roles. Thus, there is a need for new systems that utilize the unique properties that exist between full quantum coherence and classicity
  SUMMARY OF THE INVENTION
  • [0006]
    Disclosed herein are various methods of classifying the state of a system, such as a molecule interacting with its environment, in terms of its degree of order, its degree of coherence, and/or its rate of coherence decay. Some embodiments include classifying only a single one of these variables whereas other embodiments include classifying two or all three of the variables. These methods include classifying the system in the course of creating systems that exist and/or operate at a specific point or region of a classification space described the variables discussed above and all practical outcomes of such creation.
  • [0007]
    Disclosed herein is a quantum reservoir computer that includes a plurality of nodes, each node comprising at least one quantum degree of freedom that is coupled to at least one quantum degree of freedom in each other node; at least one input signal generator configured to produce at least one time-varying input signal that couples to the quantum degree of freedom; and a detector configured to receive a plurality of time-varying output signals that couple to the quantum degree of freedom.
  • [0008]
    Also disclosed herein is a method of drug discovery that includes selecting a biological target; screening a library of candidate molecules to identify a first subset of candidate molecules that bind to the biological target; determining the energy level spacing distribution of a quantum degree of freedom in each of the candidate molecules in the first subset; comparing the energy level spacing distribution to at least one pre-determined reference function; and selecting a second subset of molecules from the first subset as drug candidates based on the comparison.

  • 0009]
    Further disclosed herein is a method of drug discovery that includes selecting a biological target; screening a library of candidate molecules to identify a first subset of candidate molecules that bind to the biological target; determining the energy level spacing distribution of a quantum degree of freedom in each of the candidate molecules in the first subset; conducting an in vitro or in vivo assay for biological activity on each of the candidate molecules in the first subset; correlating the energy level spacing distribution with activity determined from the in vitro or in vivo assay; determining the energy level spacing distributions of a quantum degree of freedom in a new set of candidate molecules; comparing the energy level spacing distributions of the new set of candidate molecules with energy level spacing distributions that correlate with biological activity; and select as drug candidates from the new set of candidate molecules those molecules whose energy level spacing distributions exhibit a pre-determined level of similarity to the energy level spacing distributions that correlate with biological activity.
  • [0010]
    Further disclosed herein is a method of drug discovery that includes selecting a biological target; screening a library of candidate molecules to identify a first subset of candidate molecules that bind to the biological target; measuring decoherence decay of a quantum degree of freedom in each of the candidate molecules in the first subset; comparing the decoherence decay to at least one pre-determined reference function; and selecting a second subset of molecules from the first subset as drug candidates based on the comparison.